Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18822177 | 0.93 | MAPT (0.47) | MAPTRAB9AEGFRCYP3A4TSHR | |
| SCHEMBL19125730 | 0.90 | MAPT (0.45) | MAPTRAB9AEGFRCYP3A4TSHR | |
| SCHEMBL18797914 | 0.85 | SMN1; SMN2 (0.41) | EGFRLMNAALDH1A1 | |
| SCHEMBL18822404 | 0.81 | LMNA (0.42) | MAPTLMNA | |
| SCHEMBL7418508 | 0.80 | MAPT (0.48) | MAPTRAB9ACYP3A4TSHRLMNA | |
| SCHEMBL19111157 | 0.75 | MAPT (0.40) | MAPTLMNAALDH1A1 | |
| SCHEMBL18822207 | 0.74 | NAAA (0.36) | MAPTLMNAALDH1A1 | |
| SCHEMBL4469807 | 0.73 | MGLL (0.49) | MAPTRAB9AEGFRLMNA | |
| SCHEMBL15435813 | 0.72 | KMT2A (0.45) | RAB9ALMNAALDH1A1NPC1 | |
| SCHEMBL17775413 | 0.72 | LMNA (0.41) | RAB9ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931379-B2 | Oxyntomodulin analogs and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170196940-A1 | OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196940-A1 | OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME | PTMS, OGFRL1, SHBG | MAPT 3705/4885RAB9A 4611/4885EGFR 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.